Market Insight continues its in-depth study of PharmaNutra S.p.A. through interviews with Chairman and CEO, Roberto Lacorte, and Managing Director, […]
Great investor interest in the Company’s strategies during the virtual edition of the conference organised today by the Italian Stock […]
This has been a particularly symbolic year for PhamaNutra as 2020 marks two important anniversaries for two of the group’s […]
The No Doping Life association assigns the Play Sure Doping Free stamp to Cetilar® and ApportAL® products, and the company […]
Despite the COVID-19 emergency, the PharmaNutra Group is still strengthening its international presence through new trade agreements signed in Romania, […]
The Regatta Organising Committee has officially announced the cancellation due to the health emergency. The sporting event is postponed until […]
The innovative Sucrosomial® Magnesium developed by the PharmaNutra Group is one of the main ingredients of the new Multicentrum MyMAG […]
The Group recorded a significant +15% on the Italian market in the first three months of the current year, thanks […]
The Group obtains approval of the Cetilar® patent in the USA and new prospects unfold for SiderAL® in India thanks to […]
The Board of Directors approves the draft balance sheet and consolidated financial statement as of 31 December 2019. […]
As we all know, the spread of COVID-19 has led to a series of restrictive measures being taken by the […]
The Group will supply the products SiderAL® H and ApportAL® free of charge to the intensive care units of all […]
At this complex time for the market, PharmaNutra is strengthening its investment plan with the launch of a new campaign. […]
The Group communicates that it has signed new agreements with Casa Marzam S.A. and with Zentiva K.S. to distribute its […]
The Group’s senior management presented its results and new development prospects to the financial community, which met for the Italian […]
The food supplement market is growing in Italy and SiderAL® Forte 20 capsules is the most sold nutritional supplement in […]
Publication of the start of coverage survey drafted by Mediobanca; declaring a target price at €24.50. PharmaNutra S.p.A. has […]
International recognition continues for PharmaNutra, which, whilst commercially experiencing a strong and constant expansion in foreign markets, also continues, from […]
Sorry, this entry is only available in Italiano. Con il suo brand Cetilar®, PharmaNutra affiancherà per il primo anno il […]
The Group obtains approval of two new patents for the Sucrosomial® Technology and signs a distribution agreement for the SiderAL® […]
Specifico per la cura e l’igiene di palpebre e ciglia, il nuovo prodotto è stato presentato in occasione della Convention […]
